GB0201179D0 - Therapeutic agents - Google Patents

Therapeutic agents

Info

Publication number
GB0201179D0
GB0201179D0 GBGB0201179.9A GB0201179A GB0201179D0 GB 0201179 D0 GB0201179 D0 GB 0201179D0 GB 0201179 A GB0201179 A GB 0201179A GB 0201179 D0 GB0201179 D0 GB 0201179D0
Authority
GB
United Kingdom
Prior art keywords
sup
therapeutic agents
hcv
hepatitis
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0201179.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Original Assignee
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto di Ricerche di Biologia Molecolare P Angeletti SpA filed Critical Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Priority to GBGB0201179.9A priority Critical patent/GB0201179D0/en
Publication of GB0201179D0 publication Critical patent/GB0201179D0/en
Priority to JP2003562091A priority patent/JP4498745B2/ja
Priority to EP03700366A priority patent/EP1470113B1/en
Priority to DE60325692T priority patent/DE60325692D1/de
Priority to AT03700366T priority patent/ATE420078T1/de
Priority to CA002473508A priority patent/CA2473508A1/en
Priority to PCT/GB2003/000124 priority patent/WO2003062211A1/en
Priority to US10/500,971 priority patent/US20050130997A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
GBGB0201179.9A 2002-01-18 2002-01-18 Therapeutic agents Ceased GB0201179D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB0201179.9A GB0201179D0 (en) 2002-01-18 2002-01-18 Therapeutic agents
JP2003562091A JP4498745B2 (ja) 2002-01-18 2003-01-15 ピリミジノンウイルスポリメラーゼ阻害剤
EP03700366A EP1470113B1 (en) 2002-01-18 2003-01-15 Pyrimidinone viral polymerase inhibitors
DE60325692T DE60325692D1 (de) 2002-01-18 2003-01-15 Pyrimidinonen als virale polymerase inhibitoren
AT03700366T ATE420078T1 (de) 2002-01-18 2003-01-15 Pyrimidinonen als virale polymerase inhibitoren
CA002473508A CA2473508A1 (en) 2002-01-18 2003-01-15 Pyrimidinone viral polymerase inhibitors
PCT/GB2003/000124 WO2003062211A1 (en) 2002-01-18 2003-01-15 Pyrimidinone viral polymerase inhibitors
US10/500,971 US20050130997A1 (en) 2002-01-18 2003-01-15 Pyrimidinone viral polymerase inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0201179.9A GB0201179D0 (en) 2002-01-18 2002-01-18 Therapeutic agents

Publications (1)

Publication Number Publication Date
GB0201179D0 true GB0201179D0 (en) 2002-03-06

Family

ID=9929352

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0201179.9A Ceased GB0201179D0 (en) 2002-01-18 2002-01-18 Therapeutic agents

Country Status (8)

Country Link
US (1) US20050130997A1 (cg-RX-API-DMAC7.html)
EP (1) EP1470113B1 (cg-RX-API-DMAC7.html)
JP (1) JP4498745B2 (cg-RX-API-DMAC7.html)
AT (1) ATE420078T1 (cg-RX-API-DMAC7.html)
CA (1) CA2473508A1 (cg-RX-API-DMAC7.html)
DE (1) DE60325692D1 (cg-RX-API-DMAC7.html)
GB (1) GB0201179D0 (cg-RX-API-DMAC7.html)
WO (1) WO2003062211A1 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004062613A2 (en) 2003-01-13 2004-07-29 Bristol-Myers Squibb Company Hiv integrase inhibitors
ATE478886T1 (de) 2003-07-25 2010-09-15 Idenix Pharmaceuticals Inc Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
WO2005016384A1 (ja) * 2003-08-13 2005-02-24 Bf Research Institute, Inc. アミロイド蓄積性疾患のプローブ、アミロイド染色剤、アミロイド蓄積性疾患の治療および予防薬、ならびに神経原線維変化の診断プローブおよび染色剤
AR046938A1 (es) * 2003-12-12 2006-01-04 Merck & Co Inc Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares
CN1922174A (zh) 2004-02-20 2007-02-28 贝林格尔·英格海姆国际有限公司 病毒聚合酶抑制剂
AU2006242475B2 (en) 2005-05-02 2011-07-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
AR057456A1 (es) 2005-07-20 2007-12-05 Merck & Co Inc Inhibidores de la proteasa ns3 del vhc
US8278322B2 (en) 2005-08-01 2012-10-02 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
JP5094725B2 (ja) * 2005-10-04 2012-12-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Hivインテグラーゼ阻害剤
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
US8138164B2 (en) 2006-10-24 2012-03-20 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
CN101583372A (zh) 2006-10-24 2009-11-18 默克公司 Hcv ns3蛋白酶抑制剂
CA2667165A1 (en) 2006-10-24 2008-05-02 Merck & Co., Inc. Hcv ns3 protease inhibitors
WO2008057208A2 (en) 2006-10-27 2008-05-15 Merck & Co., Inc. Hcv ns3 protease inhibitors
JP5268927B2 (ja) 2006-10-27 2013-08-21 メルク・シャープ・アンド・ドーム・コーポレーション Hcvns3プロテアーゼ阻害剤
US8101595B2 (en) 2006-12-20 2012-01-24 Istituto di Ricerche di Biologia Molecolare P. Angletti SpA Antiviral indoles
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
MX2009011930A (es) 2007-05-04 2009-11-18 Vertex Pharma Terapia de combinacion para el tratamiento de infeccion de virus de hepatitis c.
US7763630B2 (en) 2007-06-06 2010-07-27 Bristol-Myers Squibb Company HIV integrase inhibitors
AU2008277442A1 (en) 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis C infections
CN101754974B (zh) 2007-07-19 2016-02-03 Msd意大利有限公司 作为抗病毒剂的大环化合物
WO2009018657A1 (en) * 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP2234977A4 (en) 2007-12-19 2011-04-13 Boehringer Ingelheim Int VIRAL POLYMERASE INHIBITORS
CN102014911A (zh) 2008-04-28 2011-04-13 默沙东公司 Hcv ns3蛋白酶抑制剂
ES2392611T3 (es) 2008-07-22 2012-12-12 Merck Sharp & Dohme Corp. Compuestos de quinoxalina macrocíclica como inhibidores de la proteasa NS3 del VHC
KR20110116136A (ko) 2009-01-07 2011-10-25 싸이넥시스, 인크. Hcv 및 hiv 감염의 치료에 사용하기 위한 사이클로스포린 유도체
AU2010210426B2 (en) * 2009-02-06 2015-06-11 Imago Pharmaceuticals, Inc. Inhibitors of Jun N-terminal kinase
US8143244B2 (en) 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
RU2552533C2 (ru) * 2009-03-25 2015-06-10 Эббви Инк. Противовирусные соединения и их применения
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
US8383639B2 (en) 2009-10-15 2013-02-26 Bristol-Myers Squibb Company HIV integrase inhibitors
RU2572835C2 (ru) * 2010-08-13 2016-01-20 Ф. Хоффманн-Ля Рош Аг Производные (4-метилсульфониламинофенил)-хинолина, полезные при лечении гепатита с
WO2012151567A1 (en) * 2011-05-05 2012-11-08 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for preventing and treating influenza

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2260319B (en) * 1991-10-07 1995-12-06 Norsk Hydro As Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity
DE19817265A1 (de) * 1998-04-18 1999-10-21 Bayer Ag Verwendung von Dihydropyrimidinen als Arzneimittel und neue Stoffe
WO2000013708A1 (en) * 1998-09-04 2000-03-16 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
GB0017676D0 (en) * 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase

Also Published As

Publication number Publication date
JP4498745B2 (ja) 2010-07-07
CA2473508A1 (en) 2003-07-31
EP1470113A1 (en) 2004-10-27
DE60325692D1 (de) 2009-02-26
WO2003062211A1 (en) 2003-07-31
US20050130997A1 (en) 2005-06-16
EP1470113B1 (en) 2009-01-07
ATE420078T1 (de) 2009-01-15
JP2005524627A (ja) 2005-08-18

Similar Documents

Publication Publication Date Title
DE60325692D1 (de) Pyrimidinonen als virale polymerase inhibitoren
GB0017676D0 (en) Inhibitors of viral polymerase
NZ526703A (en) Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
NZ514403A (en) Fused-ring compounds and use thereof as drugs
WO2004014852A3 (en) Iminothiazolidinones as inhibitors of hcv replication
MY140680A (en) Hepatitis c virus inhibitors
GEP20094751B (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
AU2003240488A1 (en) Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
UA83046C2 (ru) Соединения как ингибиторы вируса гепатита с, фармацевтическая композиция на их основе
WO2005054430A3 (en) Hepatitis c virus inhibitors
TR200300544T1 (tr) Erimiş siklik bileşimler ve tıbbi kullanımları
WO2005084192A3 (en) Novel 2’-c-methyl nucleoside derivatives
TW200500373A (en) 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
NO20051969L (no) Nukleosidderivater for behandling av hepatitt C virusinfeksjon.
WO2004046159A8 (en) Antiviral nucleoside derivatives
WO2004007512A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
MXPA04004621A (es) Nucleotidos, preparaciones de los mismos y su utilizacion como inhibidores de polimerasas virales de arn.
CA2480583A1 (en) Pyranon and pyrandion inhibitors of hepatitis c virus rna-dependent rna polymerase
EP1549642A4 (en) 6-METHYLPYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND ANTIVIRAL PHARMACEUTICAL COMPOSITION CONTAINING THEM

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)